Drug Information
| Drug General Information | |||||
|---|---|---|---|---|---|
| Drug ID |
D07ESH
|
||||
| Former ID |
DCL000594
|
||||
| Drug Name |
PF-1913539
|
||||
| Drug Type |
Small molecular drug
|
||||
| Indication | Alzheimer disease; Huntington's disease [ICD9: 331, 294.1, 333.4; ICD10:G30, F02.2, G10] | Discontinued in Phase 3 | [1] | ||
| Company |
Pfizer
|
||||
| Structure |
|
Download2D MOL |
|||
| Formula |
C18H15N7O
|
||||
| Canonical SMILES |
C1=CC=C(C=C1)CCN2C3=C(C=N2)C4=NC(=NN4C(=N3)N)C5=CC=CO5
|
||||
| InChI |
1S/C18H15N7O/c19-18-22-16-13(11-20-24(16)9-8-12-5-2-1-3-6-12)17-21-15(23-25(17)18)14-7-4-10-26-14/h1-7,10-11H,8-9H2,(H2,19,22)
|
||||
| InChIKey |
UTLPKQYUXOEJIL-UHFFFAOYSA-N
|
||||
| PubChem Compound ID | |||||
| PubChem Substance ID |
7980583, 10258377, 14900558, 26753254, 33500024, 47510090, 47731275, 50068074, 57395307, 76160696, 85209294, 85286114, 85788185, 90341001, 91746416, 99431535, 103180831, 103978930, 104425548, 121362004, 126671705, 129418187, 134339148, 134340512, 134341517, 135153621, 135651030, 135651205, 135697574, 142362474, 144240144, 144240145, 162023190, 162223707, 163124439, 163565213, 164759434, 170474553, 175612758, 176225385, 179294000, 184538735, 196376772, 198945991, 202558330, 204360450, 215780619, 223454701, 223519245, 223660679
|
||||
| Target and Pathway | |||||
| Target(s) | Metabotropicglutamate receptor 1 | Target Info | Antagonist | [2], [3] | |
| KEGG Pathway | Calcium signaling pathway | ||||
| FoxO signaling pathway | |||||
| Neuroactive ligand-receptor interaction | |||||
| Gap junction | |||||
| Long-term potentiation | |||||
| Retrograde endocannabinoid signaling | |||||
| Glutamatergic synapse | |||||
| Long-term depression | |||||
| Estrogen signaling pathway | |||||
| PANTHER Pathway | Heterotrimeric G-protein signaling pathway-Gq alpha and Go alpha mediated pathway | ||||
| Metabotropic glutamate receptor group III pathway | |||||
| Metabotropic glutamate receptor group I pathway | |||||
| Endogenous cannabinoid signaling | |||||
| Reactome | G alpha (q) signalling events | ||||
| Class C/3 (Metabotropic glutamate/pheromone receptors) | |||||
| WikiPathways | Hypothetical Network for Drug Addiction | ||||
| GPCRs, Class C Metabotropic glutamate, pheromone | |||||
| Gastrin-CREB signalling pathway via PKC and MAPK | |||||
| GPCR ligand binding | |||||
| GPCR downstream signaling | |||||
| GPCRs, Other | |||||
| References | |||||
| REF 1 | Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800021875) | ||||
| REF 2 | Comparative study of action mechanisms of dimebon and memantine on AMPA- and NMDA-subtypes glutamate receptors in rat cerebral neurons. Bull Exp Biol Med. 2003 Nov;136(5):474-7. | ||||
| REF 3 | Pfizer. Product Development Pipeline. March 31 2009. | ||||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.